True North Labs

Author: labstruenorth@gmail.com

  • FDA Advisory Panel Recommends Expanded Compounding Access for Six Peptides

    In a development that peptide researchers and compounding pharmacists have been watching closely, an FDA advisory panel has recommended that six specific peptide compounds remain available through compounding pharmacies. While final approval is still pending, the panel’s supportive stance is being seen as an encouraging signal for the future of peptide accessibility in the United States.

    Compounding pharmacies play a crucial role in personalized medicine, allowing licensed pharmacists to prepare customized formulations for patients based on specific clinical needs. For certain peptides that may not yet have a commercially manufactured, FDA-approved equivalent, compounding access can mean the difference between patients and practitioners having a legitimate, regulated pathway to these therapies or losing access altogether. The panel’s recommendation suggests a recognition of the value these six peptides may offer when other options are limited.

    While the specific identities of the six peptides were not detailed in the initial reporting, the broader significance lies in the process itself: an FDA advisory body taking the time to evaluate and ultimately support continued access is a meaningful step in the regulatory journey. Advisory panels often weigh scientific evidence, safety data, and clinical utility before making recommendations, and a favorable outcome here indicates that the case for these peptides’ compounding status was found reasonably compelling.

    For the peptide research and clinical community, this kind of regulatory engagement is welcome news. It reflects an ongoing dialogue between regulators and the compounding industry aimed at balancing patient safety with access to potentially beneficial therapies. Should the FDA move forward with formal approval following this panel’s input, it could provide added clarity and stability for pharmacies, prescribers, and patients who rely on these compounded formulations.

    As with any regulatory process, next steps will involve the FDA reviewing the panel’s recommendations before issuing a final determination. True North Labs will continue to monitor developments on this front and share updates as the approval process unfolds. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA panel backs compounding access for six peptides, approval still pending – Межа. Новини України.

  • FDA Advisory Panel Backs Easing Restrictions on Six Peptides

    FDA Advisory Panel Backs Easing Restrictions on Six Peptides

    In a notable development for the peptide community, a Food and Drug Administration advisory panel has voted to ease restrictions on six peptide compounds. While the FDA’s final rulemaking process is still ongoing, this vote represents a meaningful step toward potentially expanding legitimate access to these compounds for research and compounding purposes.

    Peptides have increasingly captured scientific and public interest for their roles in areas ranging from metabolic health to tissue repair. When regulatory bodies like the FDA revisit restrictions, it often reflects growing recognition of a compound’s therapeutic potential, as well as accumulating data that supports more nuanced oversight rather than blanket limitations. A panel vote to ease restrictions suggests that regulators see a path forward for these six peptides that balances safety with accessibility.

    It’s worth noting that advisory panel votes are an important part of the regulatory process, but they are not the final word. The FDA typically considers these recommendations alongside additional data, public comment, and internal review before finalizing any rule changes. Some experts involved in the discussion reportedly raised points that warrant continued attention, which is a normal and healthy part of ensuring that any regulatory shift is implemented responsibly.

    For patients, researchers, and clinicians who have been navigating a complex and sometimes restrictive regulatory landscape around peptides, this vote offers a hopeful signal. Easing restrictions—when done thoughtfully—can open doors for more research, better access to compounded formulations, and ultimately more treatment options down the line. It also reflects an evolving scientific understanding of these compounds as data continues to accumulate.

    True North Labs will continue to monitor how this process unfolds, including any final FDA decisions and the specific peptides involved. As always, regulatory changes take time to fully implement, and patients should rely on guidance from qualified healthcare providers when considering any peptide-related treatment. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA Panel Votes To Ease Restrictions on 6 Peptides—But Experts Still Have Major Concerns – health.com

  • Phase II Trial Begins Dosing Patients with LSALT Peptide, a Potential Organ-Protection Therapy

    Phase II Trial Begins Dosing Patients with LSALT Peptide, a Potential Organ-Protection Therapy

    A new Phase II clinical trial has officially begun dosing patients with LSALT peptide, an investigational therapy that researchers hope may help protect kidney and other organ function in patients undergoing high-risk medical procedures. The start of patient dosing represents a meaningful milestone in the peptide’s development, moving it further along the path toward potential clinical use.

    LSALT peptide works by inhibiting an enzyme believed to play a role in the body’s stress response during surgery or other events that place strain on the kidneys and other organs. By targeting this pathway, researchers are exploring whether the peptide can help reduce the risk of acute organ injury in vulnerable patient populations, such as those undergoing major cardiac surgery or other complex interventions where organ stress is a known concern.

    The transition from earlier-stage studies into this Phase II trial suggests that initial safety and tolerability data were encouraging enough to support continued investigation in a larger patient group. Phase II trials are typically designed to gather more information on how well a therapy performs in patients, while continuing to monitor safety closely. Positive signals at this stage often help pave the way for larger, later-phase studies that can further establish a treatment’s benefits.

    Organ protection during surgery and critical illness remains an area of significant unmet medical need, and therapies like LSALT peptide reflect the broader momentum in peptide-based research aimed at addressing complex physiological challenges. The peptide field continues to expand into new territory beyond its traditional applications, and studies like this one highlight how targeted peptide therapies may one day offer additional tools for clinicians working to safeguard patient outcomes during high-risk care.

    As dosing continues, the research team will be gathering data that could inform future development plans, including potential expansion into additional trial sites or patient populations. While it is still early in the clinical process, the initiation of this Phase II study is an encouraging sign for a therapy with the potential to support better outcomes in organ-protection care.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Patient Dosing Begins in Promising Phase II LSALT Peptide Trial – The Clinical Trial Vanguard

  • FDA Advisory Panel Votes to Ease Restrictions on Six Peptides

    An FDA advisory panel has voted to ease restrictions on six peptides, marking a notable step forward for a category of compounds that has drawn increasing interest from researchers, clinicians, and patients alike. The vote signals a potential shift in how these peptides may be accessed and studied moving forward, and it reflects a broader trend of regulators taking a closer, more nuanced look at the peptide space rather than applying blanket restrictions.

    Peptides have gained attention in recent years for their versatility across a range of applications, from metabolic health to recovery and beyond. When regulatory bodies like the FDA convene panels to specifically evaluate individual peptides, it demonstrates a level of scientific engagement that many in the field have long hoped for. A favorable vote from such a panel suggests that the available evidence and safety profiles for these six peptides were compelling enough to warrant reduced restrictions, which could pave the way for expanded research opportunities and more consistent access through appropriate channels.

    This kind of regulatory movement is significant because it can unlock further clinical investigation. When restrictions ease, it often becomes more feasible for researchers to conduct studies, for compounding pharmacies to work within clearer guidelines, and for the broader scientific community to build on existing knowledge about these compounds. This can ultimately benefit patients and practitioners who are looking for well-regulated, evidence-based options.

    It’s worth noting that easing restrictions is not the same as declaring a compound entirely free of open questions—ongoing expert dialogue and continued research are a normal and healthy part of the process as any therapeutic category matures. The fact that the FDA is actively revisiting its stance on these six peptides is itself an encouraging sign that the regulatory system is responsive to emerging science and stakeholder input. As this process continues, it will be worth watching how these changes translate into practical access and further research initiatives.

    This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA Panel Votes To Ease Restrictions on 6 Peptides—But Experts Still Have Major Concerns – Health.com

  • FDA Approves MIMRYLO (Rusfertide), a Novel Hepcidin Mimetic Peptide, for Polycythemia Vera

    The U.S. Food and Drug Administration has granted approval to MIMRYLO (rusfertide), a hepcidin mimetic peptide developed by Protagonist Therapeutics, for the treatment of polycythemia vera. This approval represents an important advancement for patients living with this chronic blood disorder, which causes the body to produce too many red blood cells, thickening the blood and increasing the risk of clotting complications.

    Rusfertide works by mimicking hepcidin, a naturally occurring hormone that regulates iron availability in the body. By modulating iron levels, the peptide helps control the overproduction of red blood cells characteristic of polycythemia vera. This mechanism offers a novel approach compared to traditional treatments, potentially giving patients and physicians an additional tool for managing the condition without relying solely on therapeutic phlebotomy or cytoreductive drugs.

    The approval of MIMRYLO highlights the growing role of peptide therapeutics in addressing complex chronic conditions through targeted, hormone-mimicking mechanisms. As a first-in-class treatment in its category, rusfertide’s success also underscores the broader potential of engineered peptides to translate biological insights into practical, approved medicines that can reach patients.

    For the polycythemia vera community, this regulatory milestone offers a new treatment option that may help improve disease management and quality of life. It also reflects continued momentum in the peptide therapeutics field, as researchers and companies explore how mimicking natural regulatory hormones can lead to effective, precisely targeted treatments for a range of conditions.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera – New Castle News

  • FDA Advisory Panel Endorses Expanded Access for First Four Peptides Under Review

    In a development that could reshape access to therapeutic peptides in the United States, an FDA advisory committee has voted to support looser regulatory pathways for the first four of seven peptides currently under review. The panel’s endorsement signals growing recognition among regulators of the therapeutic potential these compounds may offer patients.

    The review process, which examines peptides that have historically existed in a regulatory gray area, represents an important effort to bring clarity and structure to a category of compounds that many clinicians and researchers believe hold genuine promise. By moving toward formal guidelines rather than blanket restriction, the FDA appears to be acknowledging the growing body of interest and use surrounding these molecules within medical and wellness communities.

    For patients and practitioners who have followed the evolving conversation around peptide therapies, this advisory vote is an encouraging sign. A clearer regulatory framework could mean more consistent manufacturing standards, better-defined usage guidelines, and increased confidence for healthcare providers considering these options for their patients. It also opens the door for continued evaluation of the remaining three peptides still under committee review.

    While the process is still unfolding — with three more peptides awaiting their own advisory assessments — the committee’s initial four approvals suggest a thoughtful, step-by-step approach to expanding legitimate access. This measured pace, rather than an all-or-nothing ruling, may help ensure that any eventual policy changes are built on solid deliberation rather than rushed decision-making.

    As the FDA continues its review of the remaining peptides, the broader peptide research and clinical community will be watching closely. A successful outcome could pave the way for greater innovation, more research investment, and ultimately more options for patients seeking evidence-based peptide therapies under proper medical guidance.

    This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA advisers back first four of seven unapproved peptides under review for looser rules – Reuters

  • FDA Advisory Panel Backs Continued Compounding Access for Six Peptides

    FDA Advisory Panel Backs Continued Compounding Access for Six Peptides

    In a notable win for patients and prescribers who rely on compounded peptide therapies, an FDA advisory panel has recommended that six of the seven peptides under its review continue to be eligible for pharmacy compounding. This recommendation comes from a committee tasked with evaluating whether various substances meet the criteria to remain on lists that permit compounding pharmacies to prepare them for patient use.

    Compounding plays an important role in personalized medicine, allowing pharmacies to create customized formulations for patients who may need different dosages, delivery methods, or combinations not available in commercially manufactured products. For peptides in particular, compounding has been a key pathway for patients to access these therapies, especially in cases where commercial versions are limited, expensive, or unavailable in specific forms.

    The panel’s favorable recommendation for the majority of the peptides reviewed suggests that the available safety and efficacy data supported their continued inclusion on compounding lists. This is encouraging news for the broader peptide therapy community, as it indicates a level of confidence in these substances’ overall profiles from expert reviewers tasked with balancing patient access with safety considerations.

    While the specifics of which peptides received favorable votes and the reasoning behind each decision would benefit from further detail as the FDA finalizes its determinations, the overall outcome signals a generally positive regulatory environment for peptide compounding. Six out of seven represents a strong majority, suggesting that most of the substances under scrutiny demonstrated characteristics that reviewers found acceptable for continued compounding access.

    For patients and healthcare providers who have come to rely on compounded peptide formulations, this advisory panel recommendation offers reassurance that regulatory processes are actively working to maintain access where the evidence supports it. As the FDA moves toward final decisions, the peptide community will be watching closely to see how these recommendations translate into official policy.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: The (Pep)Tides Turn: FDA Panel Recommends Six of Seven for Compounding – ArentFox Schiff

  • Lilly’s Retatrutide Hits Key Goals in First Phase 3 Trial for Type 2 Diabetes

    Lilly’s Retatrutide Hits Key Goals in First Phase 3 Trial for Type 2 Diabetes

    Eli Lilly has announced encouraging results from the first Phase 3 trial of retatrutide, an investigational triple agonist peptide being studied for the treatment of type 2 diabetes. According to the company, participants who received the therapy experienced significant reductions in both A1C, a key marker of long-term blood sugar control, and body weight, two of the most important factors in managing the condition.

    Retatrutide is designed to activate three separate receptor pathways—GIP, GLP-1, and glucagon—simultaneously. This multi-receptor approach builds on the success of earlier single- and dual-agonist therapies and is intended to offer a more comprehensive metabolic effect. For people living with type 2 diabetes, therapies that can address both glucose control and weight in tandem represent a meaningful potential advance, since excess weight often complicates blood sugar management.

    The fact that these results come from a Phase 3 trial—the stage of testing that typically precedes regulatory submission—suggests retatrutide is progressing steadily through the development pipeline. Positive outcomes at this stage are an important milestone, as Phase 3 trials involve larger and more diverse patient populations and are designed to confirm the efficacy signals seen in earlier research.

    While full data details, including the magnitude of A1C and weight reductions, safety profile, and comparisons to existing treatments, will likely be shared in future peer-reviewed publications or conference presentations, the topline news is a positive sign for the broader peptide therapeutics field. Triple agonists like retatrutide reflect the growing sophistication of peptide-based drug design, and continued success in trials like this one could eventually expand the options available to patients and clinicians managing type 2 diabetes.

    As with any investigational therapy, retatrutide will need to complete the full regulatory review process before it becomes available to patients. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes – Eli Lilly

  • Gan & Lee Advances Oral Amylin Peptide ASC36 Into Phase 1 Trial for Obesity

    Gan & Lee Pharmaceuticals has officially begun a Phase 1 clinical trial in the United States for ASC36, an investigational oral amylin peptide being developed as a potential treatment for obesity. This milestone adds another promising candidate to the rapidly evolving landscape of peptide-based metabolic therapies, which have already transformed treatment options for weight management and related conditions.

    Amylin is a naturally occurring hormone that works alongside insulin to help regulate appetite and glucose levels. By targeting amylin receptor pathways, ASC36 aims to complement or potentially differentiate itself from the GLP-1 class of drugs that have dominated headlines in recent years. Notably, the fact that ASC36 is being developed as an oral formulation—rather than requiring injections—could represent a meaningful convenience advantage for patients if the drug continues to show safety and efficacy in future trials.

    Oral peptide delivery has historically been a significant technical challenge, since peptides are often broken down before they can be effectively absorbed by the body. Companies that succeed in developing effective oral versions of these therapies could greatly expand access and improve comfort for patients who prefer avoiding injections altogether. Gan & Lee’s move to bring ASC36 into human trials suggests confidence in their formulation approach and its early preclinical data.

    This Phase 1 trial will primarily focus on assessing the safety, tolerability, and pharmacokinetics of ASC36 in human participants—an essential first step before any determination can be made about its long-term effectiveness for obesity treatment. While it is still early in the clinical development process, the initiation of this trial reflects the continued momentum and innovation happening within the peptide therapeutics field, particularly as researchers explore new ways to make metabolic treatments more accessible and easier to use.

    As the obesity treatment market continues to expand, differentiated approaches like oral amylin peptides could offer valuable additional options for patients and healthcare providers alike. True North Labs will continue to monitor the progress of ASC36 and similar peptide innovations as they move through the clinical trial pipeline.

    This article is for informational purposes only and does not constitute medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Gan & Lee’s Obesity Drug ASC36 Kicks Off Phase 1 Trial in U.S.; Oral Amylin Peptide Aims for Differentiation – finance.biggo.com

  • TwoStep Therapeutics Secures $62.5 Million and FDA Clearance to Advance Novel Peptide-Drug Conjugate

    TwoStep Therapeutics has announced two significant milestones that highlight the growing momentum behind peptide-based therapeutics: an oversubscribed $62.5 million Series A financing round and FDA clearance of its Investigational New Drug (IND) application for a first-in-class peptide-drug conjugate. Together, these developments position the company to move its novel treatment approach into human clinical trials.

    The FDA’s clearance of the IND application is a pivotal regulatory achievement, allowing TwoStep Therapeutics to begin testing its peptide-drug conjugate in clinical settings. Peptide-drug conjugates represent an innovative category of therapeutics that combine the targeting precision of peptides with the therapeutic power of drug payloads, potentially allowing for more selective delivery of treatments to specific tissues or cell types while minimizing effects on healthy cells elsewhere in the body.

    The oversubscribed nature of the $62.5 million Series A round is also a notable vote of confidence from investors. When a funding round is oversubscribed, it typically means investor demand exceeded the company’s original fundraising target, reflecting strong enthusiasm for the science and the team behind it. This level of capital will likely support the company’s efforts to advance its peptide-drug conjugate through early-stage clinical development, build out its pipeline, and further explore the potential of its underlying platform technology.

    This news adds to a broader wave of investment and innovation in the peptide therapeutics space, where companies are increasingly exploring conjugate technologies as a way to enhance the precision and effectiveness of treatments. As peptide-drug conjugates continue to advance through clinical pipelines industry-wide, they may offer promising new options across a range of therapeutic areas in the years ahead.

    For now, TwoStep Therapeutics’ progress represents an encouraging example of how strong scientific foundations, regulatory progress, and investor confidence can align to push new peptide-based technologies closer to patients. As the company begins its clinical trial journey, the peptide therapeutics field will be watching closely to see how this first-in-class approach performs.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate – Business Wire